Susceptibilities to brovavir [1-B-D-arabinofuranosyl-E-5-(2-bromovinyl)-uracil] and acyclovir of clinical isolates of varicella-zoster virus obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method. All 101 isolates were significantly susceptible to brovavir; 50% effective dose of brovavir for these isolates ranged between 0.6-4.0 ng/ ml (average: 1.29 ng/ml). Brovavir was about 3,000 times more potent than acyclovir against these isolates. No marked change in the susceptibility of isolates from these patients during treatment with brovavir was observed.
Brovavir [1-B-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil; BV-araU] was re-ported to show marked antiviral activity against herpes viruses (3, 4). Particularly, its in vitro activity against varicella-zoster virus (VZV) was about 2,000 times more potent than that of acyclovir (6, 7). In addition, brovavir is very efficiently absorbed via the gastrointestinal tract and is only slightly degraded by metabolic enzyme(s) (5). Since there is now no oral antiviral drug approved for herpes zoster in Japan and the United States, these characteristics of brovavir make it very promising as a new chemotherapeutic antiviral agent for this disease.Recently, a clinical trial of oral brovavir in patients with herpes zoster was conducted in the departments of dermatology of 30 university-related hospitals by a well-controlled double-blind method. Adult immunocompetent patients within 5 days of onset of the skin eruption were subjects for the clinical study. Four groups of randomized patients received brovavir tablet at doses of either 0 (placebo control), 10, 50, or 100 mg three times a day for seven days. In nine medical facilities out of 30, which participated in the clinical study, viruses were isolated from blister fluid of the patients, and duration of virus shedding in the patients was determined in that study. Results on the clinical study and duration of virus shedding will be published elsewhere (8,11). This paper describes susceptibilities to brovavir and acyclovir of isolated VZV strains obtained from herpes zoster patients treated in Departments of Dermatology of the following nine universities;